Emerging ALK/ROS1 TKIs for NSCLC

(4:49)

Dr. Alice Shaw Returns to ALKtALK to discuss all things ALK-positive! 1/5/2025

(1:3:12)

Emerging Therapies and Combinations for ALK-Mutant NSCLC

(3:59)

How do ALK-inhibitors work in ALK-positive lung cancer?

(2:50)

Current \u0026 Emerging Approaches to Acquired Resistance for ALK/ROS1

(29:51)

Challenges in first line ALK positive NSCLC management and emerging data on ALK TKIs in ALK posi...

(13:6)

What is an ALK rearrangement in lung cancer?

(1:33)

The ALK story, a new kind of phase 1 trial

(30:49)

Are there any new drugs in the works for ALK-positive lung cancer?

(3:58)

ALK Positive Summit 2022: New Therapies to Treat ALK positive Cancers in Pre-Clinical Developments

(55:39)

ALK Positive Lung Cancer in 2023 and Beyond: Thinking Outside the Box with Dr. Alice Shaw

(42:31)

What is treatment like for ALK-positive lung cancer?

(2:12)

The therapeutic implications of EML4/ALK, ROS-1 and other new biomarkers

(22:21)

Best New Lung Cancer Treatments for ALK Mutation

(2:27)

First and Second Generation ALK Inhibitors for the Treatment of Lung Cancer

(22:10)

ALK Positive Micro-Documentary \

(6:48)

How Do the New ALK Inhibitor Drugs Compare to Xalkori (Crizotinib) for ALK+ Lung Cancer Patients?

(4:58)

New FDA-Approved Targeted Therapy For ALK Positive Lung Cancers (NSCLC) – Excellent Remission Rates!

(19:34)

New ALK Inhibitor Drugs vs Xalkori (Crizotinib) for ALK+ Lung Cancer Patients

(2:15)

Dr. Johung on Prognosis of Patients With ALK-Rearranged NSCLC and Brain Metastases

(59)